Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UCLA UCSD UCSF
Dates
study started
estimated completion
Principal Investigator
by David Smith, MD, MAS (ucsd)
Photo of David Smith
David Smith

Description

Summary

Drug studies often look at the effect one or two drugs have on a medical condition, and involve one company. There is currently an urgent need for one study to efficiently test multiple drugs from more than one company, in people who have tested positive for COVID-19 but who do not currently need hospitalization. This could help prevent disease progression to more serious symptoms and complications, and spread of COVID-19 in the community. This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. Participants in the study will be treated with either a study drug or with placebo.

Official Title

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Details

This is a master protocol to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression. The study is designed to transition from phase 2 to phase 3 in the same trial, with or without a pause in enrollment, depending on the speed of enrollment and interim results. For promising agents with limited availability, a phase 3 evaluation may occur at a later time. Up to two dose levels of the same agent may be assessed. Agents may also enter directly into phase 3 evaluation if sufficient safety and efficacy data are available from outside the trial.

Keywords

Coronavirus Covid19 COVID-19 COVID 19 Coronaviridae Infections Coronavirus Infections RNA Virus Infections Virus Diseases Nidovirales Infections SARS-CoV-2 SARS Coronavirus ACTIV-2 ACTIV2 ACTIV-2 Drug

Eligibility

You can join if…

Open to people ages 18 years and up

  • Signed informed consent.
  • Positive test for COVID-19 up to 7 days before participation in study.
  • Able to begin study treatment no later than 10 days from self-reported onset of

COVID-19 related symptom(s):

  • fever or feeling feverish
  • cough
  • shortness of breath or difficulty breathing at rest or when active
  • sore throat
  • body pain or muscle pain/aches
  • fatigue
  • headache
  • chills
  • blocked nose/nasal congestion
  • runny nose
  • loss of taste or smell
  • nausea or vomiting
  • diarrhea
  • temperature ≥ 38°C (100.4°F)
  • One or more of the following signs/symptoms within 48 hours of participating in the study:
  • fever or feeling feverish
  • cough
  • shortness of breath or difficulty breathing at rest or when active
  • sore throat
  • body pain or muscle pain/aches
  • fatigue
  • headache
  • chills
  • blocked nose/nasal congestion
  • runny nose
  • loss of taste or smell
  • nausea or vomiting
  • diarrhea
  • temperature ≥ 38°C (100.4°F)
  • Oxygen levels of ≥92% when resting (measured by study staff within 48 hours of participating in the study), unless participant is receiving long-term supplementary oxygen for an underlying lung condition.
  • Participant must agree not to participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 during the study period until hospitalization or 28 days after the start of the study, whichever occurs first.

You CAN'T join if...

  • History of or current hospitalization for COVID-19.
  • Current need for hospitalization or immediate medical attention.
  • Any use of the following medications up to 30 days before participating in the study:
  • Hydroxychloroquine (except for long-term autoimmune diseases)
  • Chloroquine and/or ivermectin (unless used for parasitic infection)
  • Remdesivir, systemic and inhaled steroids (unless used for long-term conditions)
  • HIV protease inhibitors (unless used long-term for HIV infection)
  • Receipt of plasma from a person who recovered from COVID-19 any time before participating in the study.
  • Receipt of a SARS-CoV-2 vaccine any time before participating in the study.
  • Receipt of other investigational treatments for SARS-CoV-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases).
  • Receipt of systemic steroids (e.g. prednisone, dexamethasone) or inhaled steroids up to 30 days before participating in the study, unless this is a stable dose for a long-term condition.
  • Known allergy/sensitivity or hypersensitivity to study drug or placebo.
  • Any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study.

Other investigational drug protocol-defined inclusion/exclusion criteria may apply.

Locations

  • UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100 accepting new patients
    Los Angeles California 90035 United States
  • University of California Davis Medical Center (Site 1097), 2315 Stockton Blvd. accepting new patients
    Sacramento California 95817-2201 United States
  • University of California San Diego (Site 1002), 220 Dickinson Street accepting new patients
    San Diego California 92103 United States
  • University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84 accepting new patients
    San Francisco California 94110 United States
  • Harbor UCLA (Site 1022), 1124 West Carson Street accepting new patients
    Torrance California 90502 United States

Lead Scientist at UC Health

  • David Smith, MD, MAS (ucsd)
    Davey Smith, MD, MAS, is an infectious disease specialist and translational research virologist. In his translational research, he uses basic science techniques to answer clinically relevant questions. Dr. Smith's primary research involves both figuring out how to stop the transmission of HIV and curing HIV, and he has published over 200 scientific publications in these areas.